You don't need to be signed in to read BMJ Group Blogs, but you can register here to receive updates about other BMJ Group products and services via our Group site.

Archive for June 15th, 2012

Safer prescribing of therapeutic norethisterone for women at risk of VTE

15 Jun, 12 | by shellraine, e-Media Editor

Latest Online First article

Norethisterone and VTE risk

Diana Mansour highlights a change in the Summary of Product Characteristics for Primolut N®, since data have emerged showing that, in high doses, norethisterone is partly metabolised to estradiol. This only applies to this particular progestogen, and only in high doses, not those used in contraceptive pills. Nevertheless, it could explain why studies have occasionally suggested an increased risk of venous thromboembolism with high-dose norethisterone, used therapeutically for the management of menorrhagia or dysfunctional uterine bleeding. from Anne Szarewski, Editor in Chief, JFPRHC

Latest from JFPRHC

Latest from JFPRHC